Insights

Strategic partnerships IRLAB has a notable existing collaboration where Ipsen holds exclusive global rights to mesdopetam, indicating a precedent and channel for licensing, co-development, or sublicense opportunities in CNS therapeutics.

Clinical momentum With two Phase IIb candidates (mesdopetam and pirepemat) and ongoing Phase I preclinical programs, there are multiple near-term inflection points for potential partnerships, asset licensing, or cross-promotion discussions around CNS symptom management in Parkinson's.

Expansion potential IRLAB is progressing late-stage programs while expanding its portfolio, presenting opportunities to engage in out-licensing or strategic collaborations for late-stage development, regulatory support, or regional commercialization.

Funding readiness Current funding level and reported revenues combined with recent investor-focused events indicate readiness for BD activities around partnerships, co-development deals, or milestone-driven collaborations to accelerate clinical timelines.

Executive visibility Active participation of CEO and CFO in industry events signals openness to investor relations, sponsorships, speaking engagements, and targeted outreach for BD discussions with biotech funds, pharma partners, and research collaborators.

Similar companies to IRLAB Therapeutics AB

IRLAB Therapeutics AB Tech Stack

IRLAB Therapeutics AB uses 8 technology products and services including LinkedIn Ads, RSS, WordPress, and more. Explore IRLAB Therapeutics AB's tech stack below.

Media & News

IRLAB Therapeutics AB's Email Address Formats

IRLAB Therapeutics AB uses at least 1 email format:
IRLAB Therapeutics AB Email FormatsExamplePercentage
First.Last@irlab.seJohn.Doe@irlab.se
100%

Frequently Asked Questions

What is IRLAB Therapeutics AB's official website and social media links?

Minus sign iconPlus sign icon
IRLAB Therapeutics AB's official website is irlab.se and has social profiles on LinkedIn and Crunchbase.

How much revenue does IRLAB Therapeutics AB generate?

Minus sign iconPlus sign icon
As of October 2026, IRLAB Therapeutics AB's annual revenue is estimated to be $1M - $10M.

What is IRLAB Therapeutics AB's SIC code and NAICS code?

Minus sign iconPlus sign icon
IRLAB Therapeutics AB's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does IRLAB Therapeutics AB have currently?

Minus sign iconPlus sign icon
As of October 2026, IRLAB Therapeutics AB has approximately 38 employees across 2 continents, including Europe and Asia. Key team members include Chief Executive Officer: K. T., Head Of Chemistry, Manufacturing And Controls: L. N. and Member Board Of Directors: C. N. Explore IRLAB Therapeutics AB's employee directory with LeadIQ.

What industry does IRLAB Therapeutics AB belong to?

Minus sign iconPlus sign icon
IRLAB Therapeutics AB operates in the Biotechnology Research industry.

What technology does IRLAB Therapeutics AB use?

Minus sign iconPlus sign icon
IRLAB Therapeutics AB's tech stack includes LinkedIn Ads, RSS, WordPress, CookieYes, Shopify, Microsoft 365, jQuery and TablePress.

What is IRLAB Therapeutics AB's email format?

Minus sign iconPlus sign icon
IRLAB Therapeutics AB's email format typically follows the pattern of First.Last@irlab.se. Find more IRLAB Therapeutics AB email formats with LeadIQ.

How much funding has IRLAB Therapeutics AB raised to date?

Minus sign iconPlus sign icon
As of October 2026, IRLAB Therapeutics AB has raised $48M in funding. The last funding round occurred on May 05, 2026 for $12M.

When was IRLAB Therapeutics AB founded?

Minus sign iconPlus sign icon
IRLAB Therapeutics AB was founded in 2013.
IRLAB Therapeutics AB logo

IRLAB Therapeutics AB

Biotechnology ResearchVästra Götaland, Sweden11-50 Employees

IRLAB Therapeutics AB is a biotechnology company based in Gothenburg, Västra Götaland, Sweden, focused on discovering and developing treatments for Parkinson’s disease and other CNS disorders. Its pipeline includes two advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), both in Phase IIb trials, with Ipsen holding exclusive global rights to mesdopetam since 2021. The company operates its own discovery platform, Integrative Screening Process, and is pursuing additional candidates in preclinical stages, including IRL942 and IRL757 advancing toward Phase I. IRLAB is listed on Nasdaq Stockholm, reflecting its status as a publicly traded organization in the Swedish biopharma landscape.

IRLAB focuses on addressing neurological symptoms associated with Parkinson’s disease and other CNS disorders. In 2026, the company presented results from its Phase IIb REACT-PD trial evaluating pirepemat's efficacy and safety in reducing falls among people with Parkinson’s disease at the AD/PD conference.

Section iconCompany Overview

Website
irlab.se
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2013
Employees
11-50

Section iconFunding & Financials

  • $48M

    IRLAB Therapeutics AB has raised a total of $48M of funding over 7 rounds. Their latest funding round was raised on May 05, 2026 in the amount of $12M as a Post IPO Equity.

  • $1M - $10M

    IRLAB Therapeutics AB's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.